New Companion Diagnostics Require Pharma Strategy Changes, Scientia Advisors Say
For pharma companies with blockbusters already on the market, the new diagnostic tools of personalized medicine, also known as “theranostics,” can lead to a sales decline—a possibility that should “keep drug executives up at night” developing new strategies to maintain their profit margins. - September 25, 2010
Press Releases 1 - 1 of 1